Literature DB >> 19390907

Successful treatment of severe juvenile microscopic polyangiitis with rituximab.

J Brunner1, M Freund, M Prelog, E Binder, M Sailer-Hoeck, T Jungraithmayr, C Huemer, C Sergi, L B Zimmerhackl.   

Abstract

Microscopic polyangiitis (MPA) previously called hypersensitivity angiitis is a systemic necrotizing vasculitis affecting predominantly small vessels. MPA involves multiple organ systems including the lung, the kidneys, the joints, and the skin. MPA mostly affects adults in their fourth and fifth decade of life. MPA and Wegener;s granulomatosis are grouped together as ANCA-associated vasculitis. MPA is associated with high titre of myeloperoxidase antineutrophil cytoplasmic antibodies (MPO)-ANCA. We present a 14-year-old female patient presented with MPA. She was treated with steroids and cyclophosphamide. After the complication of severe lung involvement, rituximab was administered as immune-modulating treatment. The MPA came to remission. This is the first report of a pediatric patient with MPA treated with rituximab. Rituximab might be a potential therapeutic option for relapsing ANCA associated vasculitis in childhood.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390907     DOI: 10.1007/s10067-009-1177-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

1.  Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Authors:  R Stasi; E Stipa; G Del Poeta; S Amadori; A C Newland; D Provan
Journal:  Rheumatology (Oxford)       Date:  2006-04-21       Impact factor: 7.580

2.  Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

Authors:  K G C Smith; R B Jones; S M Burns; D R W Jayne
Journal:  Arthritis Rheum       Date:  2006-09

3.  EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.

Authors:  S Ozen; N Ruperto; M J Dillon; A Bagga; K Barron; J C Davin; T Kawasaki; C Lindsley; R E Petty; A M Prieur; A Ravelli; P Woo
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

4.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.

Authors:  Richard Watts; Suzanne Lane; Thomas Hanslik; Thomas Hauser; Bernhard Hellmich; Wenche Koldingsnes; Alfred Mahr; Mårten Segelmark; Jan W Cohen-Tervaert; David Scott
Journal:  Ann Rheum Dis       Date:  2006-08-10       Impact factor: 19.103

5.  Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.

Authors:  P Eriksson
Journal:  J Intern Med       Date:  2005-06       Impact factor: 8.989

6.  [Successful treatment of a patient with refractory Wegener's granulomatosis by rituximab].

Authors:  Rumi Minami; Tomoya Miyamura; Hideyuki Watanabe; Soichiro Takahama; Masahiro Yamamoto; Eiichi Suematsu
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  2007-04

Review 7.  Challenges in the management of microscopic polyangiitis: past, present and future.

Authors:  David Jayne
Journal:  Curr Opin Rheumatol       Date:  2008-01       Impact factor: 5.006

8.  Rituximab for severe refractory pediatric Wegener granulomatosis.

Authors:  Aarat M Patel; Thomas J A Lehman
Journal:  J Clin Rheumatol       Date:  2008-10       Impact factor: 3.517

Review 9.  Targeting the B cell in vasculitis.

Authors:  Michael Walsh; David Jayne
Journal:  Pediatr Nephrol       Date:  2008-10-18       Impact factor: 3.714

10.  Childhood microscopic polyangiitis associated with MPO-ANCA.

Authors:  Amira Peco-Antic; Branka Bonaci-Nikolic; Gordana Basta-Jovanovic; Mirjana Kostic; Jasmina Markovic-Lipkovski; Milos Nikolic; Brankica Spasojevic
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.651

View more
  2 in total

Review 1.  ANCA-associated vasculitides-lessons from the adult literature.

Authors:  Joannis Vamvakopoulos; Caroline O Savage; Lorraine Harper
Journal:  Pediatr Nephrol       Date:  2010-04-01       Impact factor: 3.714

2.  Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study.

Authors:  Tanuja Chitnis; Charles R Guttmann; Alexander Zaitsev; Alexander Musallam; Bianca Weinstock-Guttman; Ann Yeh; Moses Rodriguez; Jayne Ness; Mark P Gorman; Brian C Healy; Nancy Kuntz; Dorothee Chabas; Jonathan B Strober; Emmanuelle Waubant; Lauren Krupp; Daniel Pelletier; Bradley Erickson; Niels Bergsland; Robert Zivadinov
Journal:  BMC Neurol       Date:  2013-11-13       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.